Morgan Ebert, Executive Editor

Keisha L. Gibson, MD, MPH, discusses the FDA approval of Gazyva for childhood-onset INS and its implications for relapse prevention and pediatric care.

Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.

The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.

Children with FASD given choline before age 6 had 9.1% higher nonverbal IQ and 11.3% better working memory vs placebo 5 years after treatment.

A deep learning model reading 1 nondilated fundus photo predicted 1-year progression to high myopia in children with AUCs of 0.91-0.96.

SUID was the largest single contributor to the Black-White infant mortality gap in 2024 and drove the biggest share of its rise since 2020.

Nationwide Children's experts urge early screening and family-based lifestyle change as youth-onset T2D progresses faster than adult disease.

Poison center reports of intentional school exposures rose 287% in elementary and 112% in middle school children from 2000 to 2024.

Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.

Once-daily roflumilast cream 0.05% was well tolerated in infants 3 to <24 months with AD, with 34.4% reaching vIGA-AD success at week 4.

Oral icotrokinra kept PASI 90 rates at ≥72% and IGA 0/1 at ≥70% from week 64 to 112 in ICONIC-LEAD, with no new safety signals.

Nichole Tyson, MD, outlines how pediatricians can evaluate menstrual concerns, identify red flags, and determine when specialty care is needed.

Maternal high egg and peanut intake in pregnancy and lactation did not lower infant IgE-mediated egg or peanut allergy at 1 year in PrEggNut.

Only 21.5% of 65 health institutions posted on Instagram in response to claims linking prenatal acetaminophen use with autism.

E-bike and e-scooter injuries nearly quadrupled from 2019 to 2025 at a pediatric hospital, with e-bike injuries associated with greater severity.

TikTok misinformation about prenatal acetaminophen and autism represented 28.3% of analyzed videos but generated more than half of total views.

Pediatric psychologist Jeff Temple, PhD, explains how pediatricians can help families establish healthy routines and more intentional screen use.

Interim trial findings suggest osteopathic manipulative treatment is feasible and well-tolerated in infants with positional plagiocephaly.

New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.

A teddy bear program pairs children with stuffed animals that have matching medical devices to help normalize care and reduce device-related anxiety.

Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.

More than half of firearm-owning parents of children aged 1 to 5 years reported at least 1 firearm stored unlocked, loaded, or both.

A recap of the top clinical trial and pipeline data readouts affecting pediatric care during September 2026.

Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.

A recap of the top FDA approvals/regulatory decisions/pipeline updates affecting pediatric care during September 2026.

Mavacamten becomes the first cardiac myosin inhibitor approved for adults and pediatric patients weighing 30 kg (66 lbs) or more with symptomatic oHCM.

In a 48-patient phase 1b trial, ecnoglutide was well tolerated in adolescents with obesity and reduced BMI up to 12.6% at 20 weeks.

DBV filed a BLA for the Viaskin peanut patch in peanut-allergic children aged 4-7, citing phase 3 VITESSE data, and requested priority review.

ScolimiR-3D, a 6-microRNA blood test to predict severe curve progression in AIS, received FDA Breakthrough Device designation.

Brian Vickery, MD, discusses a phase 1 trial evaluating the safety and tolerability of a microneedle stamp designed to deliver peanut protein through the skin.